Advertisement
Original Research Gynecology| Volume 228, ISSUE 3, P320.e1-320.e11, March 2023

Quality of life with relugolix combination therapy for uterine fibroids: LIBERTY randomized trials

Published:November 09, 2022DOI:https://doi.org/10.1016/j.ajog.2022.11.1278

      Background

      Symptomatic uterine fibroids are burdensome to live with; they are associated with symptom-related distress, affect daily activities, and reduce health-related quality of life. The LIBERTY randomized clinical trials showed that oral relugolix combination therapy (40 mg relugolix, 1 mg estradiol, and 0.5 mg norethindrone acetate once daily) markedly improved fibroid-associated symptoms and conditions, including heavy menstrual bleeding, pain, and anemia, and was well-tolerated.

      Objective

      This study aimed to evaluate the effect of relugolix combination therapy on the symptom burden and health-related quality of life among women with uterine fibroids.

      Study Design

      Two replicate, multinational, double-blind, 24-week, randomized, placebo-controlled, phase 3 studies, LIBERTY 1 and LIBERTY 2, were conducted in premenopausal women with uterine fibroid–associated heavy menstrual bleeding (≥80 mL per cycle for 2 cycles or ≥160 mL during 1 cycle). The symptom burden and health-related quality of life were secondary endpoints and were assessed using the validated Uterine Fibroid Symptom and Quality of Life questionnaire, which the participants completed at baseline and at week 12 and 24 of treatment. For this secondary analysis, the pooled LIBERTY 1 and LIBERTY 2 data set was used. The Uterine Fibroid Symptom and Quality of Life questionnaire is made up of a Symptom Severity scale and a Health-Related Quality of Life scale, the latter of which includes 6 subscales focusing on the following aspects of daily life: concern, activities, energy or mood, control, self-consciousness, and sexual function. The Revised Activities subscale of the Health-Related Quality of Life scale addresses the impact of uterine fibroids on physical and social activities. Symptom burden was also assessed via the Bleeding and Pelvic Discomfort subscale, a patient-reported outcome measure derived from the Uterine Fibroid Symptom Severity scale that focuses on distress from key uterine fibroid symptoms, which was a key secondary endpoint. Least squares mean changes from baseline to week 24 in the Symptom Severity scale, Bleeding and Pelvic Discomfort subscale, overall Health-Related Quality of Life scale, and the respective subscales were compared between the relugolix combination therapy and placebo groups. Responder analyses of the proportion of women who experienced a clinically meaningful change from baseline to week 24 were conducted for the Bleeding and Pelvic Discomfort and the activity subscales. A stratified Cochran-Mantel-Haenszel test, adjusted for stratification factors (region [North America vs rest of world] and baseline menstrual blood loss volume), was used for treatment comparisons.

      Results

      Across both trials, 509 women were randomized to the relugolix combination therapy or placebo groups (April 2017–December 2018). Participants on relugolix combination therapy showed a statistically significant reduction in symptom severity (−33.5 vs −12.1; nominal P<.0001) and the Bleeding and Pelvic Discomfort subscale from baseline to week 24 when compared with those on placebo treatment (−48.4 vs −17.4; nominal P<.0001). Overall, the total Health-Related Quality of Life scores improved significantly from baseline to week 24 in the relugolix combination therapy group when compared with the placebo (+37.6 vs +13.1; nominal P<.0001). Responder analyses demonstrated that more women treated with relugolix combination therapy reported a clinically meaningful reduction in the Bleeding and Pelvic Discomfort subscale and an improvement in physical and social activities when compared with those treated with the placebo (nominal P<.0001).

      Conclusion

      After 24 weeks of treatment with relugolix combination therapy, women with symptomatic uterine fibroids experienced substantial improvements in health-related quality of life with all subscales showing improvement, including emotional well-being, physical and social activities, and sexual function. In addition, women reported substantial reductions in the overall symptom burden and distress caused by key fibroid-associated symptoms.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Obstetrics & Gynecology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Stewart E.A.
        Clinical practice. Uterine fibroids.
        N Engl J Med. 2015; 372: 1646-1655
        • Laughlin S.K.
        • Stewart E.A.
        Uterine leiomyomas: individualizing the approach to a heterogeneous condition.
        Obstet Gynecol. 2011; 117: 396-403
        • Wise L.A.
        • Laughlin-Tommaso S.K.
        Epidemiology of uterine fibroids: from menarche to menopause.
        Clin Obstet Gynecol. 2016; 59: 2-24
        • Soliman A.M.
        • Margolis M.K.
        • Castelli-Haley J.
        • Fuldeore M.J.
        • Owens C.D.
        • Coyne K.S.
        Impact of uterine fibroid symptoms on health-related quality of life of US women: evidence from a cross-sectional survey.
        Curr Med Res Opin. 2017; 33: 1971-1978
        • Myers E.R.
        • Goodwin S.
        • Landow W.
        • et al.
        Prospective data collection of a new procedure by a specialty society: the fibroid registry.
        Obstet Gynecol. 2005; 106: 44-51
        • Fuldeore M.J.
        • Soliman A.M.
        Patient-reported prevalence and symptomatic burden of uterine fibroids among women in the United States: findings from a cross-sectional survey analysis.
        Int J Womens Health. 2017; 9: 403-411
        • Monleón J.
        • Cañete M.L.
        • Caballero V.
        • et al.
        Epidemiology of uterine myomas and clinical practice in Spain: an observational study.
        Eur J Obstet Gynecol Reprod Biol. 2018; 226: 59-65
        • Zimmermann A.
        • Bernuit D.
        • Gerlinger C.
        • Schaefers M.
        • Geppert K.
        Prevalence, symptoms and management of uterine fibroids: an international internet-based survey of 21,746 women.
        BMC Womens Health. 2012; 12: 6
        • Ghant M.S.
        • Sengoba K.S.
        • Recht H.
        • Cameron K.A.
        • Lawson A.K.
        • Marsh E.E.
        Beyond the physical: A qualitative assessment of the burden of symptomatic uterine fibroids on women’s emotional and psychosocial health.
        J Psychosom Res. 2015; 78: 499-503
        • Borah B.J.
        • Nicholson W.K.
        • Bradley L.
        • Stewart E.A.
        The impact of uterine leiomyomas: a national survey of affected women.
        Am J Obstet Gynecol. 2013; 209: 319.e1-319.e20
        • Hasselrot K.
        • Lindeberg M.
        • Konings P.
        • Kopp Kallner H.
        Investigating the loss of work productivity due to symptomatic leiomyoma.
        PLoS One. 2018; 13e0197958
        • Karlsson T.S.
        • Marions L.B.
        • Edlund M.G.
        Heavy menstrual bleeding significantly affects quality of life.
        Acta Obstet Gynecol Scand. 2014; 93: 52-57
        • Wallace K.
        • Zhang S.
        • Thomas L.
        • et al.
        Comparative effectiveness of hysterectomy versus myomectomy on one-year health-related quality of life in women with uterine fibroids.
        Fertil Steril. 2020; 113: 618-626
        • Laughlin-Tommaso S.K.
        • Lu D.
        • Thomas L.
        • et al.
        Short-term quality of life after myomectomy for uterine fibroids from the COMPARE-UF fibroid registry.
        Am J Obstet Gynecol. 2020; 222: 345.e1-345.e22
        • Go V.A.A.
        • Thomas M.C.
        • Singh B.
        • et al.
        A systematic review of the psychosocial impact of fibroids before and after treatment.
        Am J Obstet Gynecol. 2020; 223: 674-708.e8
        • Daniels J.
        • Middleton L.J.
        • Cheed V.
        • et al.
        Uterine artery embolisation versus myomectomy for premenopausal women with uterine fibroids wishing to avoid hysterectomy: the FEMME RCT.
        Health Technol Assess. 2022; 26: 1-74
        • Miwa K.
        • Hitaka T.
        • Imada T.
        • et al.
        Discovery of 1-{4-[1-(2,6-difluorobenzyl)-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl]phenyl}-3-methoxyurea (tak-385) as a potent, orally active, non-peptide antagonist of the human gonadotropin-releasing hormone receptor.
        J Med Chem. 2011; 54: 4998-5012
        • United States Food and Drug Administration
        Myfembree® (relugolix, estradiol, and norethindrone acetate) tablets, for oral use.
        Prescribing Information. 2022; (Available at: https://www.myovant.com/wp-content/uploads/2022/09/Approved-MYFEMBREE-PI-and-PPI_07September2022.pdf. Accessed November 26, 2022.)
      1. European Medicines Agency. Ryeqo 40mg/1mg/0.5mg film-coated tablets. Summary of Product Characteristics (SmPC) 2022. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/ryeqo. Accessed November 26, 2022.

        • Al-Hendy A.
        • Lukes A.S.
        • Poindexter 3rd, A.N.
        • et al.
        Treatment of uterine fibroid symptoms with relugolix combination therapy.
        N Engl J Med. 2021; 384: 630-642
        • Stewart E.A.
        • Lukes A.S.
        • Venturella R.
        • et al.
        Relugolix combination therapy for uterine leiomyoma–associated pain in the LIBERTY randomized trials.
        Obstet Gynecol. 2022; 139: 1070-1081
        • Spies J.B.
        • Coyne K.
        • Guaou Guaou N.
        • Boyle D.
        • Skyrnarz-Murphy K.
        • Gonzalves S.M.
        The UFS-QoL, a new disease-specific symptom and health-related quality of life questionnaire for leiomyomata.
        Obstet Gynecol. 2002; 99: 290-300
        • Hudgens S.
        • Gauthier M.
        • Hunsche E.
        • et al.
        Development of the Bleeding and Pelvic Discomfort Scale for use in women with heavy menstrual bleeding associated with uterine fibroids.
        Value Health. 2022; 25: 1986-1994
        • Hallberg L.
        • Högdahl A.M.
        • Nilsson L.
        • Rybo G.
        Menstrual blood loss - a population study. Variation at different ages and attempts to define normality.
        Acta Obstet Gynecol Scand. 1966; 45: 320-351
        • Munro M.G.
        • Critchley H.O.D.
        • Fraser I.S.
        • FIGO Menstrual Disorders Committee
        The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions.
        Int J Gynaecol Obstet. 2018; 143: 393-408
        • Coyne K.S.
        • Harrington A.
        • Currie B.M.
        • Chen J.
        • Gillard P.
        • Spies J.B.
        Psychometric validation of the 1-month recall Uterine Fibroid Symptom and health-related quality of Life questionnaire (UFS-QoL).
        J Patient Rep Outcomes. 2019; 3: 57
        • Mcleod L.D.
        • Coon C.D.
        • Martin S.A.
        • Fehnel S.E.
        • Hays R.D.
        Interpreting patient-reported outcome results: US FDA guidance and emerging methods.
        Expert Rev Pharmacoecon Outcomes Res. 2011; 11: 163-169
        • Coyne K.S.
        • Margolis M.K.
        • Murphy J.
        • Spies J.
        Validation of the UFS-QoL-hysterectomy questionnaire: modifying an existing measure for comparative effectiveness research.
        Value Health. 2012; 15: 674-679
        • Schlaff W.D.
        • Ackerman R.T.
        • Al-Hendy A.
        • et al.
        Elagolix for heavy menstrual bleeding in women with uterine fibroids.
        N Engl J Med. 2020; 382: 328-340
        • Lukes A.S.
        • Soper D.
        • Harrington A.
        • et al.
        Health-related quality of life with ulipristal acetate for treatment of uterine leiomyomas: a randomized controlled trial.
        Obstet Gynecol. 2019; 133: 869-878
        • Goodwin S.C.
        • Spies J.B.
        • Worthington-Kirsch R.
        • et al.
        Uterine artery embolization for treatment of leiomyomata: long-term outcomes from the fibroid registry.
        Obstet Gynecol. 2008; 111: 22-33
        • Feng C.
        • Meldrum S.
        • Fiscella K.
        Improved quality of life is partly explained by fewer symptoms after treatment of fibroids with mifepristone.
        Int J Gynaecol Obstet. 2010; 109: 121-124
        • Liu H.
        • Zhang J.
        • Han Z.Y.
        • et al.
        Effectiveness of ultrasound-guided percutaneous microwave ablation for symptomatic uterine fibroids: a multicentre study in China.
        Int J Hyperthermia. 2016; 32: 876-880
        • Simon J.A.
        • Al-Hendy A.
        • Archer D.F.
        • et al.
        Elagolix treatment for up to 12 months in women with heavy menstrual bleeding and uterine leiomyomas.
        Obstet Gynecol. 2020; 135: 1313-1326
        • Ng J.
        • Chwalisz K.
        • Carter D.C.
        • Klein C.E.
        Dose-dependent suppression of gonadotropins and ovarian hormones by elagolix in healthy premenopausal women.
        J Clin Endocrinol Metab. 2017; 102: 1683-1691
        • Lukes A.
        • Venturella R.
        • Al-Hendy A.
        • et al.
        O-136 once-daily relugolix combination therapy results in sustained reduction in symptoms and improved quality of life in women with uterine fibroids treated over 52 weeks.
        Hum Reprod. 2021; 36: i59-i60